Granules India receives ANDA approval for Glycopyrrolate Oral Solution
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Subscribe To Our Newsletter & Stay Updated